Vantage Point: Addressing 'opportunity leakage'

Harris Kaplan
Harris Kaplan

The traditional pharma marketing focus has been convincing physicians to prescribe their product. While prescribing remains an important prerequisite, it's only half the picture: pharma's ultimate customer is the patient.

However, patients do not always march directly to the pharmacy to fill their prescriptions, nor do they adhere to recommended regimens or stay on drug therapy. In short, patients account for a lot of “opportunity leakage” for pharma.

How to address this leakage? Despite DTC and social media, the pharma business model relies on the physician's ability to persuade patients. But leaving this crucial task to doctors could be a risky strategy. First, there is a skill issue; physicians are educated on the importance of adherence but not explicitly trained in patient persuasion.  Second is time: specifically, the ever-shorter patient visit. How much counsel can be given in a seven-minute visit?

Many pharma marketers shun “patient education.” But without pharma intervention, patient opportunity leakage will grow in lock-step with physician time pressure and payer barriers. Pharma can help physicians (and themselves) by seizing this opportunity.

In 2004, after Public Citizen recommended that Crestor be withdrawn from the market, AstraZeneca responded by establishing a physician-patient communication champion to advance the case for statins and Crestor. As part of a broad and integrated strategy, the approach was highly successful.

Physicians have said repeatedly that they appreciate pharma initiatives that add value to their practice. If the education and materials provided to a physician can improve adherence, everyone wins: the patient, the physician, payers and pharma.

Harris Kaplan is CEO of Healogix.
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.